Nevada Proposes Drug Transparency Regulations

We have written many times on the Nevada law passed in Summer 2017 that requires patient advocacy organizations to report all payments they receive from industry, regardless of the nature of the payment. The legislation was signed into law by Nevada Governor Brian Sandoval in June 2017 and now the Nevada Department of Health is working on regulations to implement the law. The current draft regulations require manufacturers and pharmacy benefit managers to submit a report by April 1st of each year for the previous calendar year that outlines the costs and rebates related to drugs listed on the List of Essential Diabetes Drugs. Pharmaceutical sales representatives that are registered with the Department during any point of the previous year are required to submit a report by March 1st. The reports for manufacturers shall include the following elements: costs of producing the drug; the total administrative expenditures (including marketing and advertising costs); the profit earned and percentage of total profit attributable to the drug; total amount of financial assistance provided through patient assistance; cost associated with coupons; the wholesale acquisition cost; history of any increase over the 5 years including percentage increase, date of increase, and explanation; aggregate amount of all rebates provided to PBM’s; any additional information prescribed by regulation by DHHS. Further, for any drugs on the list for which there was a price increase, th...
Source: Policy and Medicine - Category: American Health Authors: Source Type: blogs